Sign up to our newsletter today
We've been helping students find the right postgraduate course for over a decade.
The Department of Oncology and the Department for Continuing Education offer a part-time MSc in Experimental and Translational Therapeutics that brings together some of Oxford's leading clinicians and scientists to deliver an advanced modular programme designed for those in full-time employment, both in the UK and overseas.
The Programme draws on the world-class research and teaching in experimental therapeutics at Oxford University and offers a unique opportunity to gain an understanding of the principles that underpin clinical research and to translate this into good clinical and research practice.
Visit the website: http://www.conted.ox.ac.uk/about/msc-in-experimental-therapeutics
If your application is completed by the January deadline and you fulfill the eligibility criteria, you will
Read more about this course
For entry requirements visit the website: View Website
Fees & funding
Start dates & study options
'I am a pharmacist who, after graduation, was keen to enter the research field. I knew I could work with drugs, but I wanted to specialize in a drug research area and my interest was still broad. I foresaw that a postgraduate degree was the next step, and the MSc in Experimental Therapeutics was what I needed to understand the current challenges in good clinical and research practice. I learned to apply the skills I already had - and, at the same time, develop new ones in the theoretical and empirical context.
'The modules were really engaging and I enjoyed the challenge to demonstrate a high level of critical thinking and innovation. I also got the opportunity to get laboratory experience - and then initiated working on my one-year dissertation project, Ruthenium Compounds as Anticancer Therapeutics: Mechanisms of Action at The CRUK-MRC Oxford Institute for Radiation Oncology.
'Platinum (Pt) compounds are amongst the most clinically useful drugs used in cancer treatment; however, due to unresolved issues of toxicity seen with them in general, the search for alternative anticancer therapeutics containing other metallic elements is in progress. Ruthenium (Ru) is a transition metal that forms a scientifically attractive alternative to Pt for drug discovery in treating cancer.
'The project explored the role of the tumor suppressor protein p53 in determining cellular responses to two Ru(II) complexes. They were investigated for their cytotoxicity and potential for use as radiosensitisers, and were compared with other Pt agents.
'This work gained a 'distinction' and resulted in my co-authoring my first publication, in Nature.
'All achievements came with a lot of hard-work and excellent supervision - especially when dealing with many of the pioneers in the relevant areas. My goals were refined and I found myself genuinely interested in dealing with health data.
'This is how I am currently involved in a project on big data analysis at The George Institute for Global Health (part of The Nuffield Department of Obstetrics & Gynaecology(NDOG)). I am working on tracking physical activity (PA) from childhood into adulthood in subjects from The International Child Cardiovascular Cohort (i3C) Consortium.
'From my own experience, the MSc in Experimental Therapeutics further contributed to my personal improvement as well. I enjoyed being the student representative for my cohort and participating in meetings within the Department and the University.'
Based on your current searches we recommend the following search filters.
Based on our current search criteria we thought you might be interested in these.